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Structure of the Human Factor VIII 
C2 Domain in Complex with the 
3E6 Inhibitory Antibody
Michelle E. Wuerth, Rebecca K. Cragerud & P. Clint Spiegel
Blood coagulation factor VIII is a glycoprotein cofactor that is essential for the intrinsic pathway of 
the blood coagulation cascade. Inhibitory antibodies arise either spontaneously or in response to 
therapeutic infusion of functional factor VIII into hemophilia A patients, many of which are specific to 
the factor VIII C2 domain. The immune response is largely parsed into “classical” and “non-classical” 
inhibitory antibodies, which bind to opposing faces cooperatively. In this study, the 2.61 Å resolution 
structure of the C2 domain in complex with the antigen-binding fragment of the 3E6 classical 
inhibitory antibody is reported. The binding interface is largely conserved when aligned with the 
previously determined structure of the C2 domain in complex with two antibodies simultaneously. 
Further inspection of the B factors for the C2 domain in various X-ray crystal structures indicates 
that 3E6 antibody binding decreases the thermal motion behavior of surface loops in the C2 domain 
on the opposing face, thereby suggesting that cooperative antibody binding is a dynamic effect. 
Understanding the structural nature of the immune response to factor VIII following hemophilia A 
treatment will help lead to the development of better therapeutic reagents.
Hemophilia A is a blood clotting disorder caused by a lack of functional blood coagulation factor VIII 
(fVIII), a protein cofactor essential to the intrinsic pathway of the blood clotting cascade. Congenital 
hemophilia A, which varies in severity depending on the amount of functional fVIII present, is an 
X-linked disorder affecting 1 in 5,000 males worldwide1. The primary treatment for the disease is thera-
peutic infusions of recombinant fVIII, either in an acute or prophylactic manner2,3. The most significant 
complication to this treatment is the development of neutralizing inhibitory antibodies directed against 
the infused fVIII. Approximately 30% of patients receiving replacement therapy develop inhibitory anti-
bodies, an immune response leading to the clearance of fVIII from circulation and continued lack of 
clotting function4–6.
Coagulation fVIII is a 2,332-residue glycoprotein that is expressed with the domain arrangement of 
A1-A2-B-a3-A3-C1-C2 prior to proteolytic processing7–10. The fVIII protein circulates in the blood-
stream in its inactive form as a heterodimer, consisting of a heavy chain (A1-A2-B) and a light chain 
(a3-A3-C1-C2)11. The heterodimeric form of fVIII is noncovalently bound to the glycoprotein von 
Willebrand factor (vWF), an interaction preventing the breakdown of fVIII in circulation12–14. Following 
vascular damage, fVIII undergoes proteolytic activation by thrombin or factor Xa (fXa) to form a heter-
otrimer (A1/A2/A3-C1-C2) that dissociates from vWF and binds to activated platelet surfaces, where it 
serves as a cofactor for the serine protease factor IXa15,16. This complex, known as the intrinsic “tenase” 
complex, is responsible for converting fX to fXa at an increased rate of approximately 200,000-fold16,17.
Characterization of the immune response to fVIII has revealed that the A2 and C2 domains harbor 
the majority of epitopes recognized by inhibitory antibodies against fVIII18–21. Antibodies that garner 
specificity for the fVIII C2 domain have previously been categorized into two classes based on differing 
mechanisms of fVIII inhibition20. “Classical” antibody inhibitors are defined as inhibitors that block the 
binding of fVIII to vWF or phospholipid surfaces, which have been demonstrated to involve partially 
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overlapping sites on the C2 domain14,22–24. By contrast, “non-classical” antibody inhibitors block the pro-
teolytic activation of fVIII by thrombin or fXa, thus preventing the dissociation of fVIII from vWF20,25,26. 
For comparison, the non-classical antibodies comprise the majority of fVIII C2 domain inhibitors with 
high titers relative to the classical antibodies, which are commonly more pathogenic20,26.
Detailed structural analyses of the fVIII C2 domain in complex with inhibitory antibodies have 
allowed for the characterization of both classical and non-classical epitopes27–29. Initial structural studies 
of a high titer classical antibody inhibitor, BO2C11, in complex with the fVIII C2 domain indicated 
that the BO2C11 epitope significantly overlapped with the region proposed to be involved in membrane 
binding, which was completely sequestered upon complex formation27. Additionally, a more recent X-ray 
crystal structure of the fVIII C2 domain bound simultaneously in a ternary complex to antigen binding 
fragments (FABs) of both a classical (3E6) and non-classical (G99) antibody demonstrated that these 
inhibitors bind to opposite sides of the C2 domain with minimal overlap with the BO2C11 epitope28. 
Moreover, the classical antibody 3E6 was shown to occlude residues implicated in vWF binding30, while 
the epitope of non-classical antibody G99 included residues involved in binding both factors IXa and 
Xa31–33. Previous binding data have suggested that several classical/non-classical antibody pairs bind 
cooperatively to fVIII34,35, but no structural evidence for the observed cooperativity has been determined. 
In this study, we present the X-ray crystal structure to 2.6 Å resolution of the fVIII C2 domain in a 
binary complex with the FAB of the classical antibody 3E6. Comparisons between the C2 domain/3E6 
FAB binary structure with the C2 domain/3E6 FAB/G99 FAB ternary structure illustrate the structural con-
servation and dynamic behavior of C2 domain epitopes for classical antibody inhibitors in the presence 
and absence of non-classical antibody inhibitors.
Results and Discussion
Overall structure. The structure of the fVIII C2 domain in complex with the inhibitory antibody FAB, 
3E6, was refined to a resolution of 2.61 Å with a final Rwork and Rfree of 19.9% and 26.7%, respectively 
(Table 1). Iterative molecular replacement was performed with Phaser, which consisted of independent 
searches for two copies each of the fVIII C2 domain, the variable domain dimer and the constant domain 
dimer. The asymmetric unit contains two C2 domain/3E6 FAB complexes, which were built separately due 
to structural changes in the FAB elbow angle (Fig. 1a). Validation of the refined structure indicated 92% of 
residues are within the favored Ramachandran region (Table 1). The structure of each fVIII C2 domain 
is well resolved, consisting of a continuous chain trace from residues Cys2174- Glu2327 (chains M and 
G for complexes 1 and 2, respectively). The 3E6 FAB from complex 1 (chains A and B for the antibody 
heavy and light chains, respectively) was built to represent a complete model with the exception of resi-
dues 132–133 from chain A, which reside in a loop at the base of the constant domain. By contrast, the 
FAB from complex 2 possessed poorly resolved density for the constant domains of both the heavy and 
light chains (chains E and F, respectively). Within the FAB constant domains of complex 2, residues 177 
and 130–135 were absent from the heavy chain and residues 106, 149–154, 187–191 and 198 203 were 
absent from the light chain. Regardless of this region of poorly defined density, the fVIII C2 domain/3E6 
FAB interface was well defined by unambiguous electron density for both the C2 domain as well as the 
CDR loops for each complex.
The overall structure of the fVIII C2 domain/3E6 FAB binding interface is highly conserved. Upon 
superposition of the C2 domain and variable domains for each binary complex with the C2/3E6 portion 
of the previously determined structure of the C2 domain/3E6/G99 FAB ternary complex28, the RMSD for 
complexes 1 and 2 were calculated to be 0.328 and 0.383 for Cα atoms, respectively (Fig. 1b). The most 
significant deviation in the C2/3E6 binary crystal structure was present at the elbow angle between the 
variable and constant domains of each complex. Specifically, the C2/3E6 portion of the ternary complex 
displayed the most extended structure, with an elbow angle close to zero. By contrast, complexes 1 and 
2 possessed increasing deviations from planarity about the FAB elbow, respectively (Fig. 1b). While this 
discrepancy is notable, changes in elbow angles for FAB structures are often present and likely do not 
contribute significantly to the observed cooperativity for anti-C2 domain antibody binding36.
To further understand the solution conformation of the 3E6 FAB in complex with the fVIII C2 domain, 
each C2/3E6 binary structure was fit into a newly calculated SAXS envelope of the C2/3E6 complex from 
previously collected SAXS data29. Subsequent to manual alignment of each structure with the SAXS 
envelope, the ‘Fit in Map’ algorithm in Chimera was employed to optimize the alignment and calculate 
a correlation coefficient. While all the models fit within reason to the SAXS envelope, the C2/3E6 struc-
tures from binary complex 1 and the ternary complex yielded the highest correlation (> 0.97), indicat-
ing that the solution conformation of the C2/3E6 complex is more extended with an FAB elbow angle 
approaching 180° (Fig. 2).
The factor VIII C2 domain/3E6 FAB binding interface. The 3E6 antibody binding epitope in the 
fVIII C2 domain is highly conserved amongst the two binary complexes determined in this study along 
with the previously characterized epitope from the C2 domain/3E6/G99 FAB ternary complex28. For each 
binary complex, all residues proximal to the binding interface are fit within defined electron density 
(Supplementary Figure S1). The extent of buried surface area between the two binary complexes and 
the C2/3E6 components of the ternary complex are not significantly different. The C2 domain epitope 
consists of two loops, Glu2181-Ala2188 and Thr2202-Arg2215 (Fig.  3a,b). Backbone conformations of 
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resdiues proximal to the binding interface do not change significantly, as is the same for the sidechains 
of His2211, Gln2213, Lys2183, Arg2209 and Asp2187, all of which contribute directly to the 3E6-binding 
interface. Conformational changes are present, however, for the sidechain of Arg2215 (Fig.  3c). In the 
ternary structure, Arg2215 makes an optimal salt bridge with Asp100 of the 3E6 heavy chain. In contrast 
to this interaction, the C2/3E6 binary complex 1 indicates a single hydrogen bond between Arg2215 and 
a
90°
90°
b
fVIII C2 #1fVIII C2 #2
3E6 Fab #13E6 Fab #2
fVIII C2
3E6 variable
domains
3E6 constant
domains
Figure 1. Ribbon diagram presentation of the factor VIII C2 domain/3E6 FAB complex. (a) The 
asymmetric unit of the C2 domain/3E6 FAB complex contains two copies of the biological unit. Blue/red: 
fVIII C2 domain from complexes 1 and 2, respectively; cyan/green cyan: light and heavy chains of 3E6 
FAB from complex 1, respectively; magenta/salmon: light and heavy chains of 3E6 FAB from complex 2, 
respectively. (b) Superposition of C2 domain/3E6 complexes 1 and 2 with the C2/3E6 component of the 
C2/3E6/G99 ternary complex structure28. The alignment was limited to the C2 domain and variable domain 
structures. Green: C2/3E6 from the ternary complex; blue: C2/3E6 from binary complex 1, red: C2/3E6 from 
binary complex 2.
www.nature.com/scientificreports/
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Asp100 while complex 2 shows Arg2215 to be projecting away from D100, out of hydrogen bonding 
distance.
Following the characterization of each binding interface for both binary complexes and comparing 
them to the ternary complex, it was concluded that the mechanism for cooperativity between classical 
and non-classical anti-fVIII C2 domain inhibitory antibodies is likely not due to significant changes in 
conformation directly at the binding interface. Given that cooperativity is observed for several classical/
non-classical antibody pairs, we hypothesized that the cooperative behavior may be due to either elec-
trostatic or dynamic perturbation. Following pKa calculations with PROPKA for the fVIII C2 domain in 
isolation as well as in complex with the 3E6 antibody, it was observed that the majority of significant pKa 
perturbations occurred directly at the 3E6 interface, as expected. Specifically, residues with significant 
pKa perturbations (> 0.25 pH units) in the region of the 3E6 epitope were Glu2181, Glu2322, Lys2183, 
Lys2207, Lys2236, His2211, Arg2209, Arg2215 and Arg2320. By contrast, two residues at or near the 
non-classical G99 FAB epitope with significant pKa perturbations were His2269 (− 0.4 pH units) and 
His2315 (− 0.6 pH units).
To assess the dynamic behavior of the non-classical anti-C2 domain epitopes in the presence and 
absence of the classical inhibitory antibodies, crystallographic B factors were compared for each C2/3E6 
binary complex described herein (pdb#: 4XZU), the C2/3E6/G99 FAB ternary complex (pdb#: 4KI5), the 
C2/BO2C11 FAB complex (pdb#: 1IQD) and the isolated fVIII C2 domain (pdb#: 1D7P). While overall 
B factors are largely crystal-dependent37, the trend throughout a protein structure should be conserved 
across different crystal forms as an indication of dynamic behavior in surface loops and protein core 
rigidity. Thus, normalization of the B factors for all atoms within the fVIII C2 domain structures from 
each of the aforementioned complexes indicates that general B factor trends are similar for all complexes 
with a few notable exceptions, which are described in more detail below (Fig.  4). In order to directly 
compare distinct regions of flexibility across structures of the fVIII C2 domain, localized B factors for 
each loop were averaged and then divided by the average B factors for the entire C2 domain for each 
respective structure, which results in a ratio that describes the deviation of localized B factor values 
relative to each corresponding protein structure. To demonstrate the effectiveness of this comparative 
analysis, two loops directly at the 3E6 interface indicate specific decreases in B factors due to complex 
formation (Fig. 4b). Specifically, the Gln2213-Ser2216 loop possesses B-factor decreased ratios for each 
C2 domain in complex with the 3E6 antibody with an average of 0.91 (1.00, 0.85 and 0.87 for the ter-
nary, binary 1 and binary 2 complexes, respectively). Moreover, the 2213–2216 loop contributes to the 
epitope in the BO2C11 complex and displays a similar ratio of 0.88. By contrast, the isolated C2 domain 
possesses a significantly higher B factor ratio of 1.50 (Fig. 4d). The second major loop contributing to 
the 3E6 epitope is Glu2181-Glun2189, which displays B factor ratios of 0.82, 0.80, 0.73, 0.88 and 1.07 for 
90°
fVIII C2 domain
3E6 FAB
Figure 2. SAXS envelope of the factor VIII C2 domain/3E6 FAB complex. Based on previous SAXS data29, 
molecular envelopes were calculated with DAMMIF, averaged with DAMAVER and refined with DAMMIN. 
Rigid body modeling of the C2 domain/3E6 complex from the C2/3E6/G99 ternary structure28 was modeled 
as a rigid body into the SAXS envelope with the “Fit in Map” algorithm in Chimera.
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Figure 3. The factor VIII C2 domain/3E6 FAB binding interface. (a) The Glu2181-Ala2188 loop. Both 
Lys2183 and Asp2187 form conserved interactions with the 3E6 variable domain. (b) The Thr2202-
Arg2215 loop. Conserved interactions are present for His2211, Gln2213 and Gly2214. (c) Conformational 
heterogeneity for Arg2215 in different C2/3E6 complexes. Carbon color labeling: green: C2/3E6 from the 
ternary complex; blue/cyan: C2/3E6 from binary complex 1, red/magenta: C2/3E6 from binary complex 2.
www.nature.com/scientificreports/
6Scientific RepoRts | 5:17216 | DOI: 10.1038/srep17216
2181-2189
2197-2201
2213-2216
2223-2228
2265-2271
2275-2279
B 
Fa
ct
or
 (Å
 )2
Factor VIII C2 Domain (Atom Number)
a
b
2197-2201
2275-2279
2265-2271
2223-2228
2213-2216
2181-2189
c
C2 Domain B Factor Ratios
C2 epitope
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2213-2216 1.00 0.85 0.87 0.89 1.52
2223-2228 0.84 0.99 1.08 1.33 1.23
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Figure 4. Analysis of B factors for different factor VIII C2 domain complexes. (a) Normalized plot of 
B factors for all atoms in each C2 domain structure. Red: C2/3E6 FAB binary complex 1 (pdb#: 4XZU); 
green: C2/3E6 FAB binary complex 2 (pdb#: 4XZU); orange: the C2/3E6/G99 FAB ternary complex (pdb#: 
4KI5); blue: the C2/BO2C11 FAB complex (pdb#: 1IQD); purple: the isolated fVIII C2 domain (pdb#: 1D7P). 
(b) Structural representation of loops with different B factors relative to overall average B factors for each 
complex. VdW spheres: defined loops as defined in (d); green: factor VIII C2 domain; yellow: 3E6 variable 
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the ternary, binary 1, binary 2, BO2C11 complexes and the isolated C2 domain, respectively, showing 
that B factors are generally higher for the isolated C2 domain in contrast to the C2 domain in complex 
with classical antibodies. Interestingly, three loops that are localized to the G99 epitope also display 
decreased B factor ratios for the two C2/3E6 binary complexes (Ser2265-Trp2271, Phe2275-Lys2279 and 
Val2223-Glu2228). Significantly, the 2223–2228 loop contains Lys2227, which represents the strongest 
binding determinant for the non-classical G99 antibody20,29. Calculated B factor ratios for the C2/3E6/
G99 ternary complex and C2/3E6 binary complexes 1 and 2 were 0.83, 0.99 and 1.08, respectively, while 
the B factor ratio for this loop in the isolated C2 domain was 1.23 (Fig. 4d). Lastly, it is notable that the 
Thr2197-Ala2201 loop also possesses lower B factor ratios relative to the isolated C2 domain structure. 
While this loop does not make direct interactions with either the 3E6 or G99 epitope, it is a β –hairpin 
loop that presents solvent-exposed hydrophobic residues that bridges both 3E6 and G99 epitopes29, is a 
major component of the BO2C11 epitope27, and is hypothesized to be the site of membrane binding38–40. 
Moreover, previous H/D exchange data indicate that the 2197–2201 loop has increased protection fac-
tors upon 3E6 binding41. As a control, the X-ray crystal structures of each C2 domain in this study 
were superimposed to illustrate the overall structure of each loop in question has the same or similar 
conformation across all five structures (Fig. 4c). Taken together, these data suggest that the binding of 
the 3E6 antibody serves to decrease the dynamic mobility of not only the direct 3E6 epitope, but also 
various loops either adjacent or on the opposing side of the fVIII C2 domain structure, thus potentially 
decreasing the entropic cost to antibody binding on the non-classical face42,43.
Conclusions
In this study, we have determined the X-ray crystal structure of a classical anti-fVIII C2 domain inhibi-
tory antibody (3E6) in complex with the C2 domain from human blood coagulation factor VIII to 2.61 Å 
resolution. Inhibitory antibodies often arise following fVIII “replacement therapy” in hemophilia A 
patients, causing a significant clinical complication of uncontrolled bleeding. Previous antibody binding 
data indicate that classical and non-classical anti-fVIII antibodies bind cooperatively, but the molecular 
mechanism of this behavior has not been described. Upon comparison of the two fVIII C2 domain/3E6 
FAB complexes within this crystal form with the previously determined C2 domain/3E6/G99 FAB ternary 
complex illustrate the high level of structural conservation at the binding interface with the exception 
of Arg2215, which shows different conformers for each complex. Provided that significant structural 
changes that would explain this cooperativity were not observed directly at the C2/3E6 binding interface, 
we hypothesized that cooperative binding may be the result of perturbation of either surface electrostat-
ics or dynamics. Upon inspection of B factors for the fVIII C2 domain in each complex and in isolation, 
we determined that several loops distal to the 3E6 epitope displayed lower B factors relative to the entire 
C2 domain structure for each C2/3E6 complex. The associated decrease in mobility that is concomitant 
with lower B factors could decrease the entropic cost of binding a second, non-classical antibody, a hall-
mark of the induced fit binding mechanism often observed for antigen-antibody interactions42,43. While 
these data seem convincing that the cooperativity is a dynamic effect, they do not completely rule out 
electrostatic contributions. It should be noted that the 3E6 binding site sequesters the region of the fVIII 
C2 domain with the highest density of positive charge28,38. Given that both the 3E6 and G99 antibodies 
recognize regions of positive charge within significant portions of their respective epitopes, sequester-
ing one binding site may allow for electrostatic steering for the second antibody to bind. To conclude, 
understanding the nature of the anti-fVIII immune response will further our understanding of inhibitor 
development following fVIII replacement therapy, thus hopefully leading to the development of more 
robust, less immunogenic replacement products.
Methods
Cloning, expression and purification of proteins. Generation of purified fVIII C2 domain was 
performed as previously described28,29. The fVIII C2 domain was inserted into a pET15b expression 
vector containing an N-terminal His6 affinity tag with a thrombin cleavage site. This expression con-
struct was transformed into Escherichia coli NiCo21 cells (a BL21 (DE3) derivative) and subsequently 
grown at 37 °C in LB media in the presence of ampicillin to an OD600 of 0.6–0.8. Protein overexpres-
sion was induced upon the addition of isopropyl β –D-thiogalactopyranoside to 0.5 mM with adjustment 
of the incubation temperature to 15 °C for 16–20 hours. Overexpressed cell cultures were centrifuged 
at 8,000 rpm for 10 minutes at 4 °C (FIBERLite F10-6 × 500y rotor, Thermo Fisher Scientific), and the 
resultant cell pellet was resuspended in lysis buffer (20 mM Tris-HCl (pH 7.0), 300 mM NaCl, 10 mM imi-
dazole (pH 7.0), 0.01% (v/v) Triton X-100, and 2.5% (v/v) glycerol). Resuspended cells were lysed by the 
addition of 1 mM PMSF and 0.75 mg/mL chicken egg white lysozyme for 15–20 minutes at 4 °C followed 
domain; blue: G99 variable domain. (c) C-alpha ribbon representation of the superposition for each fVIII 
C2 domain in this study (blue: isolated C2 domain, orange: C2/BO2C11 complex, green: C2/G99/3E6 
ternary complex, red: C2/3E6 binary #1, magenta: C2/3E6 binary #2). (d) B factor ratios for surface loops 
of the factor VIII C2 domain that possess differential B factors relative to entire C2 domain structure. The 
ratios are defined as the average B factor for a given loop divided by the overall average B factor for each 
respective C2 domain structure from a given complex.
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by sonication on ice with a ½-inch titanium horn attached to a Branson 450 sonifier (50% duty cycle) 
for two cycles of 1 minute. The fVIII C2 domain-containing cell lysate was centrifuged at 16-17,000 rpm 
for 30–35 minutes at 4 °C (FIBERLite F21-8 × 50y rotor, Thermo Fisher Scientific), and the supernatant 
was subsequently filtered with 5 μ m and 0.45 μ m cellulose syringe filters, sequentially. Filtered lysate was 
applied to TALON cobalt affinity resin (Clontech, Mountain View, CA), which was pre-equilibrated with 
lysis buffer, and incubated for 1 hour at 4 °C. The lysate/resin slurry was applied to a gravity flow column 
and washed with 10 column volumes (CV) of lysis buffer, 20 CV of wash buffer I (20 mM Tris-HCl (pH 
7.2), 300 mM NaCl, 10 mM imidazole, 2.5% (v/v) glycerol), 10 CV of wash buffer II (20 mM Tris-HCl 
(pH 7.2), 150 mM NaCl, 10 mM imidazole, 2.5% (v/v) glycerol). Lastly, the hexahistidine-tagged fVIII 
C2 domain was eluted with 20 mM Tris-HCl (pH 7.2) 150 mM NaCl, 150 mM imidazole (pH 7.0), and 
2.5% (v/v) glycerol, which was immediately dialyzed into ion exchange buffer (25 mM Tris-HCl (pH 7.2), 
50 mM NaCl). The initial purified fraction of the fVIII C2 domain was further purified by ion exchange 
chromatography with a Macro-PrepTM strong cation exchange column (Bio-Rad), through a salt gradient 
from 50 to 500 mM NaCl. The eluted C2 domain was concentrated to 6–8 mg/mL and a final purifica-
tion step was completed by size exclusion chromatography with a Superdex 75 column (GE Healthcare), 
which was equilibrated ion exchange buffer.
Data Collection Statistics
 Wavelength (Å) 1.54
 Resolution range (Å) 39.77–2.609 (2.702–2.609)
 Space group P 2 21 21
 Unit cell (Å, °) a = 43.23, b = 148.49, c = 188.42, α = β = γ = 90
 Total reflections 211,017
 Unique reflections 36,886 (3,537)
 Multiplicity 5.7 (5.8)
 Completeness (%) 96.86 (93.47)
 Mean I/sigma(I) 15.20 (6.08)
 Wilson B-factor 48.03
 R-merge 0.067 (0.292)
Refinement Statistics
 Resolution (Å) 40–2.61 (2.68–2.61)
 R-work 0.1988 (0.2500)
 R-free 0.2673 (0.3491)
  Number of non-hydrogen 
atoms 9,034
  macromolecules 8,790
  ligands 3
  water 241
  Protein residues 1,137
 RMS bonds (Å) 0.011
 RMS angles (°) 1.36
 Ramachandran
  favored (%) 91
  allowed (%) 8.2
  outliers (%) 0.8
 MolProbity Clashscore 12.62
 Average B-factor (Å2) 49.4
  macromolecules 49.6
  ligands 70.1
  solvent 41.1
PDB code 4XZU
Table 1.  Crystallographic data and refinement statistics.
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The murine monoclonal hybridoma for the 3E6 antibody was generated and large-scale antibody pro-
ductions were performed previously28,29. The 3E6 mAb was purified from hybridoma supernatant with 
the NAbTM Protein A Plus spin column according to the manufacturer’s instructions (Thermo Scientific). 
The 3E6 FAB fragments were subsequently cleaved with immobilized papain (Thermo Scientific) and 
further isolated by an additional Protein A spin column step to remove the Fc regions of the IgG. The 
resultant FAB fragments were further purified by size exclusion chromatography with a Superdex 75 
column (GE Healthcare) and concentrated to 10–20 mg/mL. The C2 domain/3E6 FAB fragment binary 
complex was formed by incubation at 37 °C for 30 minutes with a 1.5-fold molar excess of the C2 domain. 
The C2/3E6 binary complex was then separated with a Superdex 75 column, concentrated to 5–10 mg/
mL, flash frozen in liquid nitrogen and stored at − 80 °C for crystallization trials.
Crystallization, data collection and structure determination. Initial crystallization conditions 
were first identified following the manual setup of 24-well sparse matrix screens by hanging drop vapor 
diffusion. Crystals suitable for diffraction studies were grown by a 1:1 ratio of 8 mg/mL C2/3E6 binary 
complex with 10 mM MES (pH 6.4-6.8) and 20% (w/v) PEG 8000. Small, disordered crystals were grown 
within the first 7–9 days, diffracting to 3.2 Å resolution while larger crystals that diffracted to 2.6 Å 
resolution grew over the period of one year. Cryoprotection of crystals was performed by the iterative 
transfer of crystals to a drop containing 10 mM MES (pH 6.5), 22% PEG 8000, and 10–30% dime-
thyl sulfoxide, and the crystals were subsequently flash-frozen in liquid nitrogen for cryogenic X-ray 
data collection. X-ray diffraction data were collected to 2.6 Å resolution on a Rigaku Micromax-007HF 
rotating anode with Confocal Varimax Optics and an RAXIS-IV+ + imaging plate detector at the Fred 
Hutchinson Cancer Research Center (Seattle, WA). Diffraction data were collected with CrystalClear 
(Rigaku) and indexed, integrated and scaled with HKL200044. Phasing was accomplished by molecu-
lar replacement with the program PHASER as incorporated into the PHENIX crystallographic soft-
ware suite45. The search models employed for molecular replacement were the isolated C2 domain 
(PDB: 1D7P), the 3E6 FAB constant domain (PDB: 4KI5), and the 3E6 FAB variable domain, which were 
searched for iteratively. Model building and refinement of the X-ray crystal structure were performed 
with COOT and PHENIX, respectively45,46. Validation of the final model from refinement was completed 
with Molprobity47. Calculations to determine pKa values were performed with PROPKA Version 3.048. 
Small angle X-ray scattering (SAXS) data were collected at the SIBYLS beamline and processed with the 
ATSAS software suite49,50. Bead models resulting from DAMMIN/DAMMIF ab initio calculations were 
converted to molecular envelopes with Situs, and rigid body alignment of the C2/3E6 binary structures 
into the SAXS-derived molecular envelopes was performed in Chimera51,52.
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